This could be huge. These are investigators that
Post# of 148187
Any success in this area will put us in the news and give a firm scientific validation we need for acceptance in the scientific/corporate communities.
Quote:
As previously announced, CytoDyn will be partnering with the American Foundation for AIDS Research (amfAR) to sponsor the HIV LATCH study which will use leronlimab to protect CCR5+ donor immune cells from HIV infection while aiming for a cure in the setting of bone marrow transplantation provided to an HIV+ recipient. It is the Company’s belief that the likelihood of success of the LATCH program was greatly enhanced with the recent announcement by investigators in Germany of a successful HIV cure using stem cells from a donor who was heterozygous for the CCR5 delta-32 mutation. Indeed, those same investigators have reached out to CytoDyn and asked if they too can run a similar LATCH program at their research center in Berlin, and we are currently taking steps to make this opportunity a reality.